RxDoctor Payments Data

Tien Ma

Primary Care · Annandale, VANPI 1962982405

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 293 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,425in general payments, 2019–2025

Across 293 payments — averaging $25.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Gilead$817
  • AstraZeneca$781
  • Novo Nordisk$579
  • Amgen$570
  • Pfizer$550
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$7,425100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,425 in reported general payments places this provider in the 95th percentile of 142 primary care providers in Virginia.

See all primary care providers in Virginia

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin27$42,345
FarxigaDapagliflozin Propanediol23$36,318
OzempicSemaglutide21$33,352
TrulicityDulaglutide22$31,772
EliquisApixaban14$25,014
JanuviaSitagliptin Phosphate14$24,079
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$20,998
AbrysvoRsv Vacc, Pref A And Pref B/Pf52$16,089
VascepaIcosapent Ethyl18$11,209
Lidocaine102$10,570
ArexvyRsvpref3 Antigen/As01e/Pf27$7,930
Diclofenac Sodium116$5,175
Clobetasol Propionate96$4,284
SymbicortBudesonide/Formoterol Fumarate13$2,923
Omega-3 Acid Ethyl Esters16$2,765

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$82$42,34527 claims
PfizerEliquis, Abrysvo$550$41,10266 claims
AstraZenecaFarxiga, Symbicort$781$39,24136 claims
Novo NordiskOzempic$579$33,35221 claims
Lilly USA, LLCTrulicity$297$31,77222 claims
GSKTrelegy Ellipta, Arexvy$304$28,92849 claims
MerckJanuvia$33$24,07914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 142 primary care providers in Virginia.

Other primary care in Annandale

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →